Aimmune Therapeutics acquired by Sociétés des Produits Nestlé S.A. / Nestlé Health Science
Sociétés des Produits Nestlé S.A. / Nestlé Health Science acquired Aimmune Therapeutics, a US therapeutics brand, on Aug 31, 2020.
Transaction summary
- Target
- Aimmune Therapeutics
- Acquirer
- Sociétés des Produits Nestlé S.A. / Nestlé Health Science
- Seller
- -
- Announced
- 2020-08-31
- Geography
- United States
- Tags
- BiopharmaceuticalsBiotechFood Allergy TherapeuticsPeanut Allergy TherapyTherapeutics
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-08-08
- Latest update
- 2026-08-08
Value and multiples
100% enterprise value
USD 2.6B
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Amounts paid and other reported values
Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.
Unknown: USD 2.6B
Supplied Google News titles and the official Nestlé press release URL describe the acquisition as valued at US$2.6 billion. The supplied evidence does not establish whether this represents enterprise value, equity value, or total consideration; other headlines cite approximately $2.0-$2.1 billion, potentially reflecting a different basis.
Basis
- USD 2.6bn transaction value is treated as publicly disclosed or derived directly from public source data.
- Valuation covers 100% of the target; the amount invested or paid for a stake is separate.
- Nestle first-party releases support the $2.6bn headline value and 13 October 2020 completion. No transaction EBITDA or defensible EBITDA multiple is retained.
Source summary
No public source summary has been published for this transaction yet.